A study on chronic lymphocytic leukemia showed that subclones with driver mutations, such as mutations of TP53, have more potential to expand during chemotherapy, and the presence of subclonal driver mutations serves as an independent risk factor for tumor progression61. Here, TP53 is linked to neoplasm.